Thromboembolic complications | | | |
Preprocedural ASA regimens | | | |
Low dose vs high dose | 0.62 (0.27 to 1.41), P=0.2 | 2.62 (1.46 to 4.69), P<0.01 | 1.18 (0.83 to 1.67), P=0.8 |
Postprocedural ASA regimens | | | |
Low dose vs high dose | 0.51 (0.22 to 1.16), P=0.1 | 2.56 (1.41 to 4.64), P<0.01
| 1.07 (0.75 to 1.51), P=0.7 |
Postprocedural clopidogrel | | | |
<6 Months vs ≥6 months | NA | NA | 1.56 (1.11 to 2.20), P<0.01
|
Postprocedural high-dose ASA | | | |
<6 Months vs ≥6 months | NA | NA | 1.19 (0.58 to 2.43), P=0.6 |
Hemorrhagic complications | | | |
Preprocedural ASA regimens | | | |
Low dose vs high-dose | 0.35 (0.11 to 1.09), P=0.06
| 1.70 (0.76 to 3.83), P=0.19 | 0.96 (0.58 to 1.64), P=0.9 |
Postprocedural ASA regimens | | | |
Low dose vs high dose | 0.77 (0.31 to 1.88), P=0.2 | 1.81 (0.79 to 4.17), P=0.15 | 1.12 (0.68 to 1.86), P=0.55 |
Postprocedural clopidogrel | | | |
<6 Months vs ≥6 months | NA | NA | 0.93 (0.55 to 1.58), P=0.79 |
Postprocedural high-dose ASA | | | |
<6 Months vs ≥6 months | NA | NA | 1.25 (0.45 to 3.51), P=0.57 |